Results of a Phase 1, Open-label, Single-dose, Parallel-group Study of Rimegepant 75 mg in Subjects with Hepatic Impairment (2126)
Ivans A, Stringfellow J, Coric V, Croop R. Results of a Phase 1, Open-label, Single-dose, Parallel-group Study of Rimegepant 75 mg in Subjects with Hepatic Impairment (2126). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2126.Peer-Reviewed Original Research